Hellen Gelband

Associate Director for Policy

Hellen Gelband has worked for 28 years in analyzing and developing U.S. and global health policy from the epidemiologic perspective. She began her career with 15 years at the Congressional Office of Technology Assessment and spent 10 years at the Institute of Medicine of The National Academies. She has worked for the World Health Organization, the University of Oxford, a number of foreign governments, and U.S.-based consulting companies. Ms. Gelband is amember of the Board of Directors of the Drugs for Neglected Diseases initiative North America. At CDDEP, she works on malaria drug use strategies and policy responses to antibiotic resistance.


16 Aug 2016

1) What are the costs and benefits of antimicrobial resistance (AMR) surveillance and 2) are the East Africa Public Health Laboratory Networking Project laboratories...

15 Sep 2015

What is the current state of antibiotic use and resistance in humans and animals around the globe? In low- and middle-income countries? What national-level strategies can help countries combat...

15 Sep 2015

How we can responsibly scale up access to antibiotics in low- and middle-income countries (LMICs) while minimizing the threat of resistance? 

22 Sep 2014
What current policies are in place in low- and middle-income countries regarding antibiotic use and resistance? What related programs are in place in these countries and how effective are they...
19 Oct 2011

Theaim of the first phase of this project is to define pathways toward...

9 Sep 2012

Has AMFm been effective? How will it continue in the future?

24 Sep 2012

Should people treated for malaria caused by P. falciparum infection take a single dose of primaquine along with primary treatment?